These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2574893)

  • 81. Discontinuation of thioridazine. Risks must be balanced.
    Bisset AF
    BMJ; 2002 Oct; 325(7370):967. PubMed ID: 12399356
    [No Abstract]   [Full Text] [Related]  

  • 82. The efficacy and acceptability of hybrid electroconvulsive therapy compared with standard electroconvulsive therapy for schizophrenia patients: A parallel-group, double-blind, randomized, controlled trial.
    Li J; Deng WF; Xu SX; Jiang ZY; Rong H; Kong XM; Xie XH
    Brain Stimul; 2021; 14(3):737-739. PubMed ID: 33962078
    [No Abstract]   [Full Text] [Related]  

  • 83. Further observations on TPS-23, a thioridazine derivative.
    Shelton WH; Gallant DM; Bishop MP
    J New Drugs; 1965; 5(6):343-4. PubMed ID: 5327281
    [No Abstract]   [Full Text] [Related]  

  • 84. Acute visual loss after thioridazine overdose.
    Anderton L; Bishop P
    Am J Psychiatry; 2001 May; 158(5):818. PubMed ID: 11329415
    [No Abstract]   [Full Text] [Related]  

  • 85. Use of verapamil to treat negative symptoms in schizophrenia.
    Price WA; Pascarzi GA
    J Clin Psychopharmacol; 1987 Oct; 7(5):357. PubMed ID: 3680609
    [No Abstract]   [Full Text] [Related]  

  • 86. Somatic profiles in chronic schizophrenia.
    Howard JS
    Psychosomatics; 1976; 17(1):26-31. PubMed ID: 5744
    [No Abstract]   [Full Text] [Related]  

  • 87. Antipsychotic effect of gamma-type endorphins in schizophrenia.
    van Ree JM; de Wied D; Verhoeven WM; van Praag HM
    Lancet; 1980 Dec 20-27; 2(8208-8209):1363-4. PubMed ID: 6109172
    [No Abstract]   [Full Text] [Related]  

  • 88. [THE HALOPERIDOL-THIORIDAZINE THERAPEUTIC COMBINATION].
    BORGHESI R
    Rass Studi Psichiatr; 1964; 53():627-32. PubMed ID: 14281654
    [No Abstract]   [Full Text] [Related]  

  • 89. Methysergide in mania: a double-blind comparison with thioridazine.
    McNamee HB; Le Poidevin D; Naylor GJ
    Psychol Med; 1972 Feb; 2(1):66-9. PubMed ID: 4551987
    [No Abstract]   [Full Text] [Related]  

  • 90. [THERAPEUTIC RESULTS AND PRELIMINARY CONSIDERATIONS OF A BUTYRROPHENONE TREATMENT (HALOPERIDOL AND TRIPERIDOL) COMBINED WITH THIORIDAZINE IN CHRONIC SCHIZOPHRENIC SUBJECTS].
    CIBELLI S; SABBATINI F
    Gazz Med Ital; 1965 Mar; 124():101-8. PubMed ID: 14334151
    [No Abstract]   [Full Text] [Related]  

  • 91. Effects of thioridazine on chronically regressed patients.
    Fleischl H
    J Am Geriatr Soc; 1967 Jan; 15(1):29-33. PubMed ID: 6015542
    [No Abstract]   [Full Text] [Related]  

  • 92. Massive edema induced by thioridazine (Mellaril): an unusual complication.
    Margolis J
    J Am Geriatr Soc; 1972 Dec; 20(12):593-4. PubMed ID: 4639424
    [No Abstract]   [Full Text] [Related]  

  • 93. [ON THE ACTION OF A NEW PHARMACOLOGIC FORM OF A PHENOTHIAZINE DERIVATIVE, SLOW ACTING THIORIDAZINE, IN SCHIZOPHRENICS].
    BORGHESI R; MEDAGLINI E
    Rass Studi Psichiatr; 1965; 54():55-78. PubMed ID: 14304500
    [No Abstract]   [Full Text] [Related]  

  • 94. A comparison of the slow-release and the regular forms of thioridazine; a double-blind controlled study in hospitalized psychiatric patients.
    VESTRE ND; MACNAUGHTON DV; SCHIELE BC
    Curr Ther Res Clin Exp; 1963 Apr; 5():183-94. PubMed ID: 13996972
    [No Abstract]   [Full Text] [Related]  

  • 95. Criteria for measuring change: statistical significance vs clinical significance.
    Manchanda R
    Br J Psychiatry; 1986 Jun; 148():744-5. PubMed ID: 3779258
    [No Abstract]   [Full Text] [Related]  

  • 96. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
    Tardy M; Huhn M; Kissling W; Engel RR; Leucht S
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009268. PubMed ID: 25007358
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Thioridazine for schizophrenia.
    Fenton M; Rathbone J; Reilly J; Sultana A
    Cochrane Database Syst Rev; 2007 Jul; 2007(3):CD001944. PubMed ID: 17636691
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
    Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial.
    Borison RL; Sinha D; Haverstock S; McLarnon MC; Diamond BI
    Psychopharmacol Bull; 1989; 25(2):190-3. PubMed ID: 2574893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.